PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced results from a Phase 2 study of BMS-986165, an investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis. Efficacy endpoints including ≥75% and 90% reduction in the Psoriasis Area and Severity Index (PASI 75, PASI 90) …
Tag Archives: tyrosine kinase inhibitor
September, 2018
January, 2018
-
31 January
Seattle Genetics to Acquire Cascadian Therapeutics for $614 Million, Adding Late-Stage Breast Cancer Program
att BOTHELL, Wash. & SEATTLE–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc. (Nasdaq:CASC) today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximately $614 …
October, 2017
-
4 October
Celgene and Nimbus Enter Immunology Alliance to Develop Programs for Autoimmune Disorders
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today the initiation of a long-term strategic alliance with Celgene Corporation (NASDAQ: CELG) in immunology. Under the terms of the agreement, Celgene will receive an option to acquire each program in the alliance …
January, 2017
-
25 January
Eisai’s Lenvatinib Meets Primary Endpoint in Late-Stage Hepatocellular Carcinoma Study
WOODCLIFF LAKE, N.J., Jan. 25, 2017 /PRNewswire/ — Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company’s multiple receptor tyrosine kinase inhibitor, lenvatinib (marketed as Lenvima®), for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). The trial achieved …
July, 2016
-
18 July
AstraZeneca’s Tagrisso Meets Main Goal in Late-Stage Lung Cancer Study
18 July 2016 — AstraZeneca today announced that the Phase III AURA3 trial met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The AURA3 randomised trial assessed the efficacy and safety of Tagrisso as a 2nd-line treatment in more than 400 patients with EGFR T790M …
-
8 July
Pfizer’s Sutent Meets Primary Endpoint in its Late-Stage Kidney Cancer Trial
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving disease-free survival (DFS) as determined by blinded independent central review in patients with renal cell …
May, 2016
-
16 May
FDA Expands Approval of Eisai’s Lenvima in Kidney Cancer
WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an …